Summary
Vertex Pharmaceuticals Incorporated (VRTX) has filed an 8-K report on February 12, 2026, announcing its consolidated financial results for the fourth quarter and full fiscal year ended December 31, 2025. While the specific financial figures are detailed in the press release (Exhibit 99.1), this filing serves as the official notification to the market of these results. Investors should refer to the press release for critical performance indicators, revenue streams, profitability, and any forward-looking statements or guidance provided by the company.
Key Highlights
- 1Vertex Pharmaceuticals reported its Q4 and full-year 2025 financial results on February 12, 2026.
- 2The financial results pertain to the period ending December 31, 2025.
- 3The press release containing detailed financial information is attached as Exhibit 99.1.
- 4This filing incorporates by reference the information provided in the press release.
- 5The report includes consolidated financial results for both the three and twelve months ended December 31, 2025.
- 6Investors are directed to Exhibit 99.1 for comprehensive financial details.
Frequently Asked Questions
The primary purpose of this 8-K filing is to announce and provide access to Vertex Pharmaceuticals' consolidated financial results for the fourth quarter and the full fiscal year ended December 31, 2025, through an accompanying press release.
The detailed financial results are provided in the press release dated February 12, 2026, which is attached to this 8-K filing as Exhibit 99.1 and incorporated by reference.
The filing clearly states the results are for the three and twelve months ended December 31, 2025.
As per the filing, the information in Exhibit 99.1 is not deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, nor is it subject to the liabilities of that section, unless expressly incorporated by reference into a registration statement or other filing.